A recent study has shown that anti-obesity treatment appears to be effective and without serious side effects in children, but the importance of these outcomes can only be emphasized through long-term follow-up. The study published today by New England Journal of Medicine (NEJM), one of the largest medical journals, stated that the new treatment Liraglutide is an older version of the popular GLP-1 drugs, which include Ozempic, which treats obesity in adults. It also outweighs another treatment in weight change and body mass index in children aged 6 to 12 years, according to this study. Liraglutide is an older GLP-1 agonist, sold under the brand name Saxenda by Danish pharmaceutical giant Novo Nordisk, which also makes the blockbuster semaglutide drugs Ozempic and Wegovy. It may constitute a therapeutic revolution, although a large number of researchers and doctors are still dealing with these treatments with caution pending further research in the coming stages. Researchers hailed these findings as an enc ouraging step in the treatment of obesity in children, who are currently not advised any treatment in this area. A senior lecturer in physiology at Anglia Ruskin University Simon Cork said that it was positive news that Liraglutide was safe and effective in children, emphasizing the need for more studies over longer periods to make sure that appetite suppression does not have consequences later in children's development. Source: Qatar News Agency